These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36479971)

  • 1. Critical roles for 'housekeeping' nucleases in type III CRISPR-Cas immunity.
    Chou-Zheng L; Hatoum-Aslan A
    Elife; 2022 Dec; 11():. PubMed ID: 36479971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A type III-A CRISPR-Cas system employs degradosome nucleases to ensure robust immunity.
    Chou-Zheng L; Hatoum-Aslan A
    Elife; 2019 Apr; 8():. PubMed ID: 30942690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases.
    Walker FC; Chou-Zheng L; Dunkle JA; Hatoum-Aslan A
    Nucleic Acids Res; 2017 Feb; 45(4):2112-2123. PubMed ID: 28204542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system.
    Hatoum-Aslan A; Maniv I; Samai P; Marraffini LA
    J Bacteriol; 2014 Jan; 196(2):310-7. PubMed ID: 24187086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and Purification of the Cas10-Csm Complex from Staphylococci.
    Chou-Zheng L; Hatoum-Aslan A
    Bio Protoc; 2017 Jun; 7(11):. PubMed ID: 28835904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.
    Samai P; Pyenson N; Jiang W; Goldberg GW; Hatoum-Aslan A; Marraffini LA
    Cell; 2015 May; 161(5):1164-1174. PubMed ID: 25959775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The host-encoded RNase E endonuclease as the crRNA maturation enzyme in a CRISPR-Cas subtype III-Bv system.
    Behler J; Sharma K; Reimann V; Wilde A; Urlaub H; Hess WR
    Nat Microbiol; 2018 Mar; 3(3):367-377. PubMed ID: 29403013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.
    Wakefield N; Rajan R; Sontheimer EJ
    FEBS Lett; 2015 Oct; 589(20 Pt B):3197-204. PubMed ID: 26364721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity.
    Rostøl JT; Marraffini LA
    Nat Microbiol; 2019 Apr; 4(4):656-662. PubMed ID: 30692669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of an active type III-A CRISPR effector complex.
    Smith EM; Ferrell S; Tokars VL; Mondragón A
    Structure; 2022 Aug; 30(8):1109-1128.e6. PubMed ID: 35714601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interference Requirements of Type III CRISPR-Cas Systems from Thermus thermophilus.
    Karneyeva K; Kolesnik M; Livenskyi A; Zgoda V; Zubarev V; Trofimova A; Artamonova D; Ispolatov Y; Severinov K
    J Mol Biol; 2024 Mar; 436(6):168448. PubMed ID: 38266982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of a Type III-A CRISPR-Cas effector complex reveals conserved and idiosyncratic contacts to target RNA and crRNA among Type III-A systems.
    Paraan M; Nasef M; Chou-Zheng L; Khweis SA; Schoeffler AJ; Hatoum-Aslan A; Stagg SM; Dunkle JA
    PLoS One; 2023; 18(6):e0287461. PubMed ID: 37352230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ruler protein in a complex for antiviral defense determines the length of small interfering CRISPR RNAs.
    Hatoum-Aslan A; Samai P; Maniv I; Jiang W; Marraffini LA
    J Biol Chem; 2013 Sep; 288(39):27888-97. PubMed ID: 23935102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.